We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Letters were sent to healthcare professionals about Zinbryta▼ (daclizumab beta), Lynparza 50 mg capsules, and radium-223-dichloride (Xofigo▼).
The use of daclizumab (daclizumab beta) is now restricted to adults with relapsing multiple sclerosis who have had an inadequate response to at least 2 other disease-modifying therapies (DMTs) and for whom other DMTs are contraindicated or unsuitable. Do not...
The CMA investigated the anticipated acquisition by Experian Limited of Credit Laser Holdings Limited (ClearScore)
Claridon Group becomes the first privately owned British company to establish an office in Burma.
First published during the 2010 to 2015 Conservative and Liberal Democrat coalition government
Letters were sent about cladribine (Litak and Leustat), radium-223-dichloride (Xofigo▼), and ERWINASE.
Updated advice for healthcare professionals is available, after conclusion of a review of the safety of idelalisib, including the risk of infection.
The CMA has referred Clariant’s anticipated acquisition of Kilfrost’s de-/anti-icing fluids (ADF) business for an in-depth investigation.
The CMA has cancelled its merger investigation into Clariant’s anticipated acquisition of Kilfrost’s de-/anti-icing fluids business.
The European Medicines Agency (EMA) has recommended the immediate suspension of the marketing authorisation and recall of daclizumab (Zinbryta) in the EU following reports of serious inflammatory brain disorders, including encephalitis and meningoencephalitis, in patients with multiple sclerosis.
The CMA has published an issues statement in its investigation into Clariant’s anticipated acquisition of Kilfrost’s de-/anti-icing fluids business.
OFT closed case: Anticipated acquisition by Shin-Etsu Chemical Company of Clariant's cellulose ethers business.
Letter from Professor David Salisbury concerning the recall of a batch of the influenza vaccine, Preflucel.
There are new interim treatment recommendations for idelalisib for chronic lymphocytic leukaemia and follicular lymphoma in light of new findings from clinical trials outside its currently authorised drug combinations or indicated populations.
The CMA investigated the completed acquisition by Acadia Healthcare Company, Inc. of Priory Group No. 1 Limited.
Environment Agency has unveiled new fishing licence images
Rt Hon the Lord Luce to become Chairman of the Crown Nominations Commission for its selection of the next Archbishop of Canterbury to succeed the Most Reverend and Rt Hon Rowan Williams
Britannia Pharmaceuticals Ltd has issued a company-led drug alert for Denzapine 50mg/ml Oral Suspension (CLDA (18)A/03)
Statement by Ambassador Karen Pierce, UK Permanent Representative to the UN, at the Security Council meeting requested by Russia on the Salisbury attack.
First published during the 2016 to 2019 May Conservative government
Mediation can be a quicker, cheaper and more amicable alternative to court.
A summary of safety letters sent to healthcare professionals in August 2016
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).